Spruce Biosciences Inc
NASDAQ:SPRB

Watchlist Manager
Spruce Biosciences Inc Logo
Spruce Biosciences Inc
NASDAQ:SPRB
Watchlist
Price: 82.12 USD -9.46% Market Closed
Market Cap: 87.9m USD

Spruce Biosciences Inc
Change in Working Capital

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Spruce Biosciences Inc
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
Spruce Biosciences Inc
NASDAQ:SPRB
Change in Working Capital
-$8.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Change in Working Capital
-$2.3B
CAGR 3-Years
-2%
CAGR 5-Years
N/A
CAGR 10-Years
-31%
Gilead Sciences Inc
NASDAQ:GILD
Change in Working Capital
$7.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
27%
Amgen Inc
NASDAQ:AMGN
Change in Working Capital
$10.4B
CAGR 3-Years
N/A
CAGR 5-Years
102%
CAGR 10-Years
20%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Change in Working Capital
-$811.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-16%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Change in Working Capital
$440.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
9%
No Stocks Found

Spruce Biosciences Inc
Glance View

Market Cap
87.9m USD
Industry
Biotechnology

Spruce Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Daly City, California and currently employs 15 full-time employees. The company went IPO on 2020-10-09. The firm is focused on developing and commercializing therapies for rare endocrine disorders. The firm's development product candidate, tildacerfont, is a non-steroidal therapy that offers disease control for patients suffering from congenital adrenal hyperplasia (CAH). Tildacerfont is a potent and selective, non-steroidal, oral, small-molecule antagonist of the corticotropin-releasing hormone receptor 1 (CRF1) receptor, which is a regulator of the production of adrenocorticotropic hormone (ACTH). Its CAHmelia-203, is a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with CAH with poor disease control. Its CAHmelia-204, is a second Phase IIb clinical trial in adult patients with CAH with good disease control focused on glucocorticoid reduction. The company has also conducted two Phase IIa clinical trials of tildacerfont in adult patients with CAH on stable glucocorticoid therapy.

SPRB Intrinsic Value
116.84 USD
Undervaluation 30%
Intrinsic Value
Price

See Also

What is Spruce Biosciences Inc's Change in Working Capital?
Change in Working Capital
-8.6m USD

Based on the financial report for Dec 31, 2024, Spruce Biosciences Inc's Change in Working Capital amounts to -8.6m USD.

Back to Top